Indication: Urothelial Cancer
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Sub-indication: Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1
Line of Therapy: 2nd line
Principal Investigator: Chandler Park, M.D.
Sponsor: Immunomedics, Inc
Email for more information: GU-NCIResearch@nortonhealthcare.org